BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32660824)

  • 1. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
    Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
    Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of DNA damage level in peripheral blood lymphocytes of chemotherapy-naïve patients with germ cell cancer.
    Sestakova Z; Kalavska K; Hurbanova L; Jurkovicova D; Gursky J; Chovanec M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rejlekova K; Sycova-Mila Z; Cingelova S; Spanik S; Mardiak J; Chovanec M; Mego M
    Oncotarget; 2016 Nov; 7(46):75996-76005. PubMed ID: 27732956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
    Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
    Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
    Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
    Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
    Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
    Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
    Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
    Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of plasma miR-371a-3p in germ cell tumors.
    Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
    J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
    Gonzalez-Billalabeitia E; Castellano D; Sobrevilla N; Guma J; Hervas D; Luengo MI; Aparicio J; Sanchez-Muñoz A; Mellado B; Saenz A; Valverde C; Fernandez A; Margeli M; Duran I; Fernandez S; Sastre J; Ros S; Maroto P; Manneh R; Cerezuela P; Carmona-Bayonas A; Ayala de la Peña F; Luis Aguilar J; Rivera S; García Del Muro X; Germà-Lluch JR;
    J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
    Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
    BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
    Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
    Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA damage levels in peripheral blood mononuclear cells before and after first cycle of chemotherapy have comparable prognostic values in germ cell tumor patients.
    Ivovič D; Šestáková Z; Roška J; Kálavská K; Hurbanová L; Holíčková A; Smolková B; Kabelíková P; Novotná V; Chovanec M; Palacka P; Mego M; Jurkovičová D; Chovanec M
    Front Oncol; 2024; 14():1360678. PubMed ID: 38496757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
    Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival in metastatic germ-cell cancer.
    Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
    Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1.
    Pectasides D; Papaxoinis G; Nikolaou M; Valavanis C; Aravantinos G; Fountzilas G; Tamvakis N; Pectasides E; Lekka I; Arapantoni-Dadioti P; Zizi A; Ghiconti I; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):737-44. PubMed ID: 19331230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
    Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
    Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.